GlassScriptPhysician profile
David A Franco
NPI 1821041955
$2,758.38
in general payments reported to CMS, 2019-2025
30 companies · $1,009 in 2025
The $1,009 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $14.33 · 2021: $82.90 · 2022: $288 · 2023: $561 · 2024: $804 · 2025: $1,009.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,372.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $756.94 | 2021-2025 | |
| Celgene Corporation | $251.76 | 2023-2025 | Zeposia |
| Boston Scientific Corporation | $159.44 | 2022-2024 | Watchman Flx |
| Teva Pharmaceuticals USA, INC. | $138.00 | 2021-2025 | Austedo Xr, Austedo Xr |
| Genentech USA, INC. | $132.62 | 2023-2025 | Ocrevus Zunovo, Ocrevus |
| Argenx US, INC. | $125.98 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Vanda Pharmaceuticals INC. | $124.75 | 2025 | Ponvory |
| Biogen, INC. | $89.38 | 2025 | |
| Ge Healthcare | $84.49 | 2021-2025 | |
| Ucb, INC. | $82.88 | 2023-2025 | Rystiggo |
| Cycle Pharmaceuticals INC | $75.85 | 2024-2025 | Tascenso Odt, Bafiertam |
| Lundbeck LLC | $70.61 | 2023-2024 | Rexulti, Vyepti |
| Emd Serono, INC. | $69.73 | 2024 | |
| Amneal Pharmaceuticals LLC | $66.70 | 2024-2025 | Crexont, Rytary |
| Amgen INC. | $63.67 | 2023 | Aimovig |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $54.52 | 2023-2025 | Nourianz |
| Csl Behring | $52.28 | 2023-2024 | Hizentra |
| Sk Life Science, INC. | $51.24 | 2023-2025 | |
| Lilly USA, LLC | $50.75 | 2023-2025 | Amyvid, Kisunla |
| Tg Therapeutics, INC. | $42.51 | 2024 | |
| Janssen Pharmaceuticals, INC | $40.97 | 2022 | |
| Eisai INC. | $31.49 | 2020-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $26.80 | 2022 | |
| Abbott Laboratories | $23.51 | 2023 | Infinity |
| Pfizer INC. | $17.83 | 2023 | |
| Tanabe Pharma America, INC. | $15.34 | 2023 | |
| Avion Pharmaceuticals | $15.25 | 2022 | |
| Neurocrine Biosciences, INC. | $14.39 | 2023 | Ingrezza |
| Aucta Pharmaceuticals, INC. | $14.38 | 2025 | Motpoly Xr |
| Axsome Therapeutics, INC. | $14.32 | 2025 | Symbravo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Franco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.